Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4)

June 12, 2019
PACIFIC-4
Lung Cancer
Brian Myre, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

Sponsor: AstraZeneca

https://clinicaltrials.gov/ct2/show/NCT03833154

  • Stage I to II NSCLC, lymph node-negative (T1 to T3N0M0)
  • Completion of SoC SBRT as definitive treatment prior to randomization
  • Life expectancy of at least 12 weeks
  • Body weight >30 kg
  • Patients with central or peripheral lesions are eligible
  • No mixed small cell and non-small cell cancer histology

6 years

Accepting Participants
Interventional
III
Kathy Seymour, BSN
630-646-6075
630-646-6110
630-646-6072